Historic Move Could Transform Psilocybin Access for Terminally Ill Patients
The DEA requested that federal health officials conduct a medical review of psilocybin - a watershed moment for psychedelic medicine.
Read More
Aspen Skier’s Remarkable Recovery: Could Psychedelics Transform Brain Injury Treatment?
Doctors predicted six months of inpatient rehabilitation, but Hall walked out in six weeks. His secret? Psychedelic mushrooms.
Read More
Breakthrough Psychedelic Drug Shows Promise in Treating Postpartum Depression
Reunion Neuroscience announced positive results from its RECONNECT Phase 2 clinical trial evaluating postpartum depression.
Read More
Ketamine Therapy Cost Roundup: August 2025
We reviewed recent patient reports on public communities, with our internal messaging in early August 2025 to gauge out of pocket prices for ketamine therapy. Figures are self reported, vary by protocol, and reflect local market conditions rather than clinical guidance. Where possible, we include direct quotes from individuals in each region to provide more […]
Read More
Psychedelic Therapy Market Surges Toward $10 Billion Future
The psychedelic drugs market is poised for explosive growth, with projections going from $3.63 billion in 2024 to $10.11 billion by 2032.
Read More
PharmaTher Achieves Historic Ketamine FDA Approval After Third Attempt
PharmaTher has secured FDA approval for its ketamine product KETARx, which is specifically for surgical pain management.
Read More
7 Hidden Revenue Leaks Killing Your Ketamine Practice’s Profitability
These revenue leaks often remain invisible until they accumulate into thousands of lost income each month. Let's help you fix them.
Read More
Scientists Test LSD Microdoses on Anxious Dogs With Surprising Results
A groundbreaking case study reveals that tiny amounts of LSD may offer new hope for dogs suffering from separation anxiety.
Read More
Record High Suicide Deaths Signal Urgent Need for Innovation
More than 49,000 Americans died by suicide in 2022, representing a 3% jump over the previous year and the highest number in U.S. history.
Read More
Johnson & Johnson’s Spravato Surges Toward Blockbuster Status
Johnson & Johnson's depression nasal spray Spravato continues its impressive growth trajectory, generating $414 million in Q2 2025 revenue.
Read More